Seeking Alpha

BMO steps to sidelines on Ambit following quizartinib news

  • BMO cuts Ambit Biosciences (AMBI -29.7%) to Market Perform from Outperform.
  • The shares are struggling mightily today on the heels of Tuesday's quizartinib news.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector